EA201301107A1 - Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) - Google Patents

Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Info

Publication number
EA201301107A1
EA201301107A1 EA201301107A EA201301107A EA201301107A1 EA 201301107 A1 EA201301107 A1 EA 201301107A1 EA 201301107 A EA201301107 A EA 201301107A EA 201301107 A EA201301107 A EA 201301107A EA 201301107 A1 EA201301107 A1 EA 201301107A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
antibodies against
factor inhibitor
Prior art date
Application number
EA201301107A
Other languages
English (en)
Other versions
EA034214B1 (ru
Inventor
Чжучжи Ван
Джон Мёрфи
Тобиас Марквардт
Дитер Мосмайер
Original Assignee
Байер Хелфкеа Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Хелфкеа Ллк filed Critical Байер Хелфкеа Ллк
Publication of EA201301107A1 publication Critical patent/EA201301107A1/ru
Publication of EA034214B1 publication Critical patent/EA034214B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Обеспечиваются изолированные моноклональные антитела, которые связываются со специфическими эпитопами ингибитора пути тканевого фактора человека (TFPI), и изолированные молекулы нуклеиновой кислоты, кодирующие их. Также обеспечиваются фармацевтические композиции, которые включают анти-TFPI моноклональные антитела и способы лечения дефицитов или пороков коагуляции путем введения антител.
EA201301107A 2011-04-01 2012-03-30 Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты EA034214B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number Publication Date
EA201301107A1 true EA201301107A1 (ru) 2014-11-28
EA034214B1 EA034214B1 (ru) 2020-01-17

Family

ID=46932389

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201301107A EA034214B1 (ru) 2011-04-01 2012-03-30 Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
EA201991704A EA201991704A3 (ru) 2011-04-01 2012-03-30 Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201991704A EA201991704A3 (ru) 2011-04-01 2012-03-30 Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (ru)
EP (1) EP2694544B1 (ru)
JP (4) JP6170903B2 (ru)
KR (2) KR101995302B1 (ru)
CN (2) CN103797030B (ru)
AU (3) AU2012236296A1 (ru)
BR (1) BR112013025376A2 (ru)
CA (2) CA3068997A1 (ru)
CL (1) CL2013002811A1 (ru)
CO (1) CO6890074A2 (ru)
CR (1) CR20130499A (ru)
CU (1) CU20130128A7 (ru)
CY (1) CY1121538T1 (ru)
DK (1) DK2694544T3 (ru)
DO (1) DOP2013000218A (ru)
EA (2) EA034214B1 (ru)
EC (1) ECSP13012913A (ru)
ES (1) ES2722824T3 (ru)
GT (1) GT201300229A (ru)
HK (1) HK1243426A1 (ru)
HR (1) HRP20190467T1 (ru)
HU (1) HUE042706T2 (ru)
IL (4) IL228633B (ru)
LT (1) LT2694544T (ru)
MX (1) MX2013011218A (ru)
MY (2) MY190951A (ru)
PE (1) PE20141149A1 (ru)
PH (4) PH12013502039A1 (ru)
PL (1) PL2694544T3 (ru)
PT (1) PT2694544T (ru)
RS (1) RS58633B1 (ru)
SG (2) SG193594A1 (ru)
SI (1) SI2694544T1 (ru)
TR (1) TR201905101T4 (ru)
UA (1) UA113623C2 (ru)
WO (1) WO2012135671A2 (ru)
ZA (1) ZA201308169B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977846B1 (ko) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
CN102325795B (zh) † 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
NZ602115A (en) 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
MX2013011218A (es) * 2011-04-01 2013-10-17 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
NZ629130A (en) * 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105209497B (zh) * 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
US9556280B2 (en) 2013-03-15 2017-01-31 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
EA036490B1 (ru) * 2015-02-25 2020-11-17 Могам Инститьют Фор Байомедикал Рисерч Антитела, связывающиеся с tfpi, и содержащая их композиция
SG10201912817YA (en) * 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102325795B (zh) * 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
NZ602115A (en) * 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2013011218A (es) * 2011-04-01 2013-10-17 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
US20190194353A1 (en) 2019-06-27
CA2831907A1 (en) 2012-10-04
IL228633A0 (en) 2013-12-31
TR201905101T4 (tr) 2019-05-21
JP6170903B2 (ja) 2017-07-26
JP2018172411A (ja) 2018-11-08
US20140294832A1 (en) 2014-10-02
US20170107298A1 (en) 2017-04-20
SI2694544T1 (sl) 2019-06-28
DOP2013000218A (es) 2013-11-15
EP2694544A4 (en) 2015-03-25
CO6890074A2 (es) 2014-03-10
PH12019500441A1 (en) 2020-10-12
EP2694544A2 (en) 2014-02-12
ZA201308169B (en) 2016-03-30
AU2019201814A1 (en) 2019-04-04
EA034214B1 (ru) 2020-01-17
EA201991704A3 (ru) 2020-06-30
HK1243426A1 (zh) 2018-07-13
HRP20190467T1 (hr) 2019-05-03
CR20130499A (es) 2013-10-24
LT2694544T (lt) 2019-04-25
PH12019500439A1 (en) 2020-10-12
CN107090046A (zh) 2017-08-25
IL283829A (en) 2021-07-29
WO2012135671A2 (en) 2012-10-04
US20180194857A1 (en) 2018-07-12
CN103797030B (zh) 2017-05-31
AU2017203105A1 (en) 2017-06-01
KR20140019428A (ko) 2014-02-14
ECSP13012913A (es) 2014-02-28
PH12013502039B1 (en) 2013-12-16
JP6363747B2 (ja) 2018-07-25
CA3068997A1 (en) 2012-10-04
RS58633B1 (sr) 2019-05-31
UA113623C2 (uk) 2017-02-27
HUE042706T2 (hu) 2019-07-29
SG10201602606UA (en) 2016-04-28
CA2831907C (en) 2020-03-24
EP2694544B1 (en) 2019-01-23
KR101995302B1 (ko) 2019-07-02
KR20190079698A (ko) 2019-07-05
PH12013502039A1 (en) 2013-12-16
GT201300229A (es) 2014-11-13
CL2013002811A1 (es) 2014-02-28
CU20130128A7 (es) 2014-03-26
PT2694544T (pt) 2019-04-02
SG193594A1 (en) 2013-10-30
EA201991704A2 (ru) 2020-03-31
JP2021019619A (ja) 2021-02-18
AU2012236296A1 (en) 2013-10-24
PL2694544T3 (pl) 2019-07-31
NZ615969A (en) 2016-01-29
JP2014511685A (ja) 2014-05-19
JP2017113019A (ja) 2017-06-29
MX2013011218A (es) 2013-10-17
IL274686B (en) 2021-09-30
PE20141149A1 (es) 2014-08-28
US20220041752A1 (en) 2022-02-10
IL257145A (en) 2018-03-29
BR112013025376A2 (pt) 2017-07-25
IL274686A (en) 2020-06-30
CN103797030A (zh) 2014-05-14
IL228633B (en) 2018-03-29
ES2722824T3 (es) 2019-08-19
MY165499A (en) 2018-03-27
WO2012135671A3 (en) 2012-12-13
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
DK2694544T3 (en) 2019-04-15
CY1121538T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201390993A1 (ru) Антитела к cd38
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201401204A1 (ru) Антитела к il-23p19
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201400447A1 (ru) АНТИТЕЛА К CD1d
TN2015000277A1 (en) Bmp-6 antibodies
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
EA201390117A1 (ru) Композиция антител к vegfr-3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU